{"id":"human-fecal-microbiota-mbiotix-hbi","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (abdominal pain, diarrhea, constipation)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Infection or sepsis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This biotherapeutic product contains a standardized preparation of human fecal microbiota designed to restore microbial diversity and function in the patient's intestinal tract. By reintroducing beneficial bacteria and restoring eubiotic conditions, it aims to treat conditions associated with dysbiosis, particularly recurrent Clostridioides difficile infection and potentially other gastrointestinal and metabolic disorders.","oneSentence":"MBiotix HBI is a human fecal microbiota transplant that restores a healthy gut microbiome composition to treat microbiota-associated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:40.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Recurrent Clostridioides difficile infection"},{"name":"Primary or secondary prevention of C. difficile infection"}]},"trialDetails":[{"nctId":"NCT07371013","phase":"NA","title":"Fecal Microbiota Transplantation in Children With Autism Spectrum Disorder and Gastrointestinal Symptoms","status":"NOT_YET_RECRUITING","sponsor":"Institute of Mother and Child, Warsaw, Poland","startDate":"2026-01","conditions":"Autism Spectrum Disorder, Gastrointestinal Symptoms","enrollment":20},{"nctId":"NCT04824222","phase":"PHASE3","title":"The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2021-04","conditions":"Covid19","enrollment":366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MBiotix HBI"],"phase":"phase_3","status":"active","brandName":"Human fecal microbiota, MBiotix HBI","genericName":"Human fecal microbiota, MBiotix HBI","companyName":"Medical University of Warsaw","companyId":"medical-university-of-warsaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MBiotix HBI is a human fecal microbiota transplant that restores a healthy gut microbiome composition to treat microbiota-associated diseases. Used for Recurrent Clostridioides difficile infection, Primary or secondary prevention of C. difficile infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}